Stacie B. Dusetzina

Best Publications

• Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia

  Stacie B. Dusetzina;Aaron N. Winn;Gregory A. Abel;Haiden A. Huskamp

  557
  Citations

• Impact of FDA drug risk communications on health care utilization and health behaviors: a systematic review.

  Stacie B. Dusetzina;Ashley S. Higashi;E. Ray Dorsey;Rena Conti

  235
  Citations

• Financial Toxicity in Adults With Cancer: Adverse Outcomes and Noncompliance

  Thomas G. Knight;Allison M. Deal;Stacie B Dusetzina;Hyman Bernard Muss

  195
  Citations

• A Policy Prescription for Reducing Health Disparities-Achieving Pharmacoequity.

  Utibe R Essien;Stacie B Dusetzina;Walid F Gellad

  162
  Citations

• Cost-effectiveness of tyrosine kinase inhibitor treatment strategies for chronic myeloid leukemia in chronic phase after generic entry of imatinib in the United States

  William V. Padula;Richard A. Larson;Stacie B. Dusetzina;Jane F. Apperley

  146
  Citations

• Drug Pricing Trends for Orally Administered Anticancer Medications Reimbursed by Commercial Health Plans, 2000-2014

  Stacie B. Dusetzina

  119
  Citations

• Many Medicare Beneficiaries Do Not Fill High-Price Specialty Drug Prescriptions.

  Unknown

  116
  Citations

• Financial Relationships With Industry Among National Comprehensive Cancer Network Guideline Authors

  Aaron P. Mitchell;Ethan M. Basch;Stacie B. Dusetzina

  116
  Citations

• Treating depression after initial treatment failure: directly comparing switch and augmenting strategies in STAR*D.

  Bradley N. Gaynes;Stacie B. Dusetzina;Alan R. Ellis;Richard A. Hansen;Richard A. Hansen

  107
  Citations

• Specialty Drug Pricing and Out-of-Pocket Spending on Orally Administered Anticancer Drugs in Medicare Part D, 2010 to 2019

  Stacie B. Dusetzina;Haiden A. Huskamp;Nancy L. Keating

  103
  Citations

• Trends in Inpatient and Outpatient Hysterectomy and Oophorectomy Rates Among Commercially Insured Women in the United States, 2000-2014.

  Kemi M. Doll;Stacie B. Dusetzina;Whitney Robinson

  93
  Citations

• The impact of out-of-pocket costs on the use of intrauterine contraception among women with employer-sponsored insurance.

  Lydia E. Pace;Stacie B. Dusetzina;A. Mark Fendrick;Nancy L. Keating

  86
  Citations

• Cost-Related Medication Nonadherence and Desire for Medication Cost Information Among Adults Aged 65 Years and Older in the US in 2022

  Unknown

  83
  Citations

• Cost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALGB 70604 (Alliance).

  Charles L. Shapiro;James P. Moriarty;Stacie Dusetzina;Andrew L. Himelstein

  80
  Citations

• Financial Toxicity of Cancer Treatment

  Unknown

  78
  Citations

• Association of Prescription Drug Price Rebates in Medicare Part D With Patient Out-of-Pocket and Federal Spending.

  Stacie B. Dusetzina;Rena M. Conti;Nancy L. Yu;Peter B. Bach

  72
  Citations

• Mind the Gap: Why Closing the Doughnut Hole Is Insufficient for Increasing Medicare Beneficiary Access to Oral Chemotherapy

  Stacie B. Dusetzina;Nancy L. Keating

  70
  Citations

• Control Outcomes and Exposures for Improving Internal Validity of Nonrandomized Studies

  Stacie B Dusetzina;M Alan Brookhart;Matthew L Maciejewski

  63
  Citations

• Pharmaceutical Industry Payments and Oncologists' Selection of Targeted Cancer Therapies in Medicare Beneficiaries.

  Aaron P. Mitchell;Aaron N. Winn;Stacie B. Dusetzina

  53
  Citations

• For Uninsured Cancer Patients, Outpatient Charges Can Be Costly, Putting Treatments Out Of Reach

  Stacie B. Dusetzina;Ethan Basch;Nancy L. Keating

  43
  Citations